Cohort Study on Treatment of Cardiovascular Diseases With Traditional Chinese Medicine
CSCD-TCM plus
1 other identifier
observational
20,000
1 country
1
Brief Summary
This is a cohort study performed in patients with cardiovascular diaeases who were treated with oral Chinese medicine and Western medicine. Collect indicators such as the incidence of cardiovascular events, all due to readmission, all due to death. To hospital using clinical samples to detect genomics, proteomics, metabolomics, intestinal flora and sclerotia.To explore the clinical efficacy of Chinese patent medicine in the treatment of cardiovascular diseases, and provide reliable data support for its clinical application.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2021
CompletedFirst Submitted
Initial submission to the registry
March 25, 2022
CompletedFirst Posted
Study publicly available on registry
April 4, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2031
ExpectedApril 4, 2022
March 1, 2022
2.4 years
March 25, 2022
March 25, 2022
Conditions
Outcome Measures
Primary Outcomes (3)
Cardiovascular Events Cardiovascular Events Cardiovascular Events
Non-fatal myocardial infarction, non-fatal ischemic stroke, unplanned hemodynamic reconstruction.
one year
All due to readmission
Readmission for cardiovascular events and readmission for other reasons.
one year
All due to death
Cardiac death and death from other causes.
one year
Study Arms (2)
Exposed group
Western medicine treatment with Chinese medicine treatmen
Non-exposed group
Western medicine treatment
Interventions
Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill, etc.
Eligibility Criteria
The collaboration network of coronary heart disease research medical units formed by the research group, including The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, The Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin Chest Hospital, Tianjin Hospital of ITCWM Nankai Hospital and Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital#a total of 6 hospitals.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tianjin University of Traditional Chinese Medicine
Tianjin, China
Related Publications (1)
Yang T, Zheng H, Pan G, Guo R, Liu F, Liu S, Tao S, Li L, Yang R, Yu C. Relationship between the circulating N-terminal pro B-type natriuretic peptide and the risk of carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a CSCD-TCM plus study in China. Cardiovasc Diabetol. 2023 Nov 2;22(1):299. doi: 10.1186/s12933-023-02015-y.
PMID: 37919791DERIVED
Biospecimen
Blood, Urine, feces, saliva, tongue coating
MeSH Terms
Conditions
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- researcher
Study Record Dates
First Submitted
March 25, 2022
First Posted
April 4, 2022
Study Start
November 1, 2021
Primary Completion
April 1, 2024
Study Completion (Estimated)
November 1, 2031
Last Updated
April 4, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will share